PTAB Takes On Rituxan Patent, Won't Expand Follow-On Rule
The Patent Trial and Appeal Board on Thursday agreed to review the entirety of a Biogen Inc. patent covering its lymphomas biologic Rituxan, and shot down the drugmaker's attempt to apply...To view the full article, register now.
Already a subscriber? Click here to view full article